Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to -$386879.0.

  • Cumberland Pharmaceuticals' Cash from Financing Activities rose 2793.35% to -$386879.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.4 million, marking a year-over-year decrease of 853954.21%. This contributed to the annual value of $196904.0 for FY2024, which is 10265.21% up from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Cash from Financing Activities stood at -$386879.0, which was up 2793.35% from -$150797.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Cash from Financing Activities high stood at $3.9 million for Q1 2022, and its period low was -$5.5 million during Q1 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' median Cash from Financing Activities value was -$1.2 million (recorded in 2022), while the average stood at -$995087.5.
  • Within the past 5 years, the most significant YoY rise in Cumberland Pharmaceuticals' Cash from Financing Activities was 40185.87% (2022), while the steepest drop was 61985.77% (2022).
  • Cumberland Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$735300.0 in 2021, then plummeted by 278.19% to -$2.8 million in 2022, then skyrocketed by 46.52% to -$1.5 million in 2023, then increased by 7.31% to -$1.4 million in 2024, then skyrocketed by 71.93% to -$386879.0 in 2025.
  • Its Cash from Financing Activities stands at -$386879.0 for Q3 2025, versus -$150797.0 for Q2 2025 and -$5.5 million for Q1 2025.